Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Charles River Laboratories Intl. Inc (CRL) vs Intel Corp (INTC) Price & Performance

Charles River Laboratories Intl. IncTrade
Intel CorpTrade

Price performance (Past 24H)

Key statistics

Charles River Laboratories Intl. Inc vs Intel Corp — how do they compare? Charles River Laboratories Intl. Inc trades at $231 (market cap $11.14B), while Intel Corp trades at $110.5 (market cap $541.60B). The key difference: Intel Corp is far larger — about 48.6× Charles River Laboratories Intl. Inc's market cap, and Intel Corp pays a 2.24% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals.

CRLINTC
Market Cap
$11.14B$541.60B
Sector
HealthTechnology
52-Week High
$233.60$140.94
52-Week Low
$145.57$19.31
Enterprise Value
$14.00B$553.84B
Volume
43,552,012
Dividend Yield
2.24%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Charles River Laboratories Intl. Inc

Charles River Laboratories (CRL) trades at $229.75, down 1.57% on the day, near its consensus price target of $229.80. The stock shows a bullish technical trend with strong moving average signals and support at $225. Fundamentally, CRL has beaten EPS estimates for three consecutive quarters but reported a net loss of $144.34 million in 2025, with negative profit margins. Recent news highlights collaborations in AI and NGS services, supporting growth prospects.

Outlook remains mixed: analyst consensus is strongly bullish with 72% buy ratings and a high target of $260, but profitability challenges and high P/E of 684.85 pose risks. Cash flow stability and strategic partnerships offer upside, while margin pressures and debt levels require monitoring for sustained recovery.

Intel Corp

Intel (INTC) trades at $103.12, down 6.12% today, as the stock faces technical bearish signals despite recent earnings beats. The company shows mixed fundamentals with negative net income margins and high valuation ratios, though operating cash flow remains strong at $9.7 billion. Recent news highlights Intel's $5.7 billion AI investment in Ireland while analysts express caution about near-term challenges in the semiconductor sector.

Intel presents a complex investment case with improving operational trends but persistent profitability challenges. The stock offers potential upside to the $105.48 consensus target but faces headwinds from competitive pressures and high capital expenditures. Key catalysts include AI execution and PC market recovery, while risks include margin compression and debt levels.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Charles River Laboratories Intl. Inc

Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.

Read more on CRL

About Intel Corp

Intel Corporation designs, manufactures, and sells computer components and related products. The Company major products include microprocessors, chipsets, embedded processors and microcontrollers, flash memory, graphic, network and communication, systems management software, conferencing, and digital imaging products.

Read more on INTC